Literature DB >> 25740989

Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.

Wendy E Walker1, Sebastian Kurscheid2, Samit Joshi2, Charlie A Lopez3, Gerald Goh4, Murim Choi4, Lydia Barakat2, John Francis2, Ann Fisher2, Michael Kozal2, Heidi Zapata2, Albert Shaw2, Richard Lifton5, Richard E Sutton6, Erol Fikrig7.   

Abstract

UNLABELLED: Elite controllers (ECs) are a rare group of HIV seropositive individuals who are able to control viral replication without antiretroviral therapy. The mechanisms responsible for this phenotype, however, have not been fully elucidated. In this study, we examined CD4(+) T cell resistance to HIV in a cohort of elite controllers and explored transcriptional signatures associated with cellular resistance. We demonstrate that a subgroup of elite controllers possess CD4(+) T cells that are specifically resistant to R5-tropic HIV while remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses. Transcriptome analysis revealed 17 genes that were differentially regulated in resistant elite controllers relative to healthy controls. Notably, the genes encoding macrophage inflammatory protein 1α (MIP-1α), CCL3 and CCL3L1, were found to be upregulated. The MIP-1α, MIP-1β, and RANTES chemokines are natural ligands of CCR5 and are known to interfere with HIV replication. For three elite controllers, we observed increased production of MIP-1α and/or MIP-1β at the protein level. The supernatant from resistant EC cells contained MIP-1α and MIP-1β and was sufficient to confer R5-tropic resistance to susceptible CD4(+) T cells. Additionally, this effect was reversed by using inhibitory anti-MIP antibodies. These results suggest that the T cells of these particular elite controllers may be naturally resistant to HIV infection by blocking R5-tropic viral entry. IMPORTANCE: HIV is a pandemic health problem, and the majority of seropositive individuals will eventually progress to AIDS unless antiretroviral therapy (ART) is administered. However, rare patients, termed elite controllers, have a natural ability to control HIV infection in the absence of ART, but the mechanisms by which they achieve this phenotype have not been fully explored. This paper identifies one mechanism that may contribute to this natural resistance: some elite controllers have CD4(+) T cells that produce high levels of MIP chemokines, which block R5-tropic HIV entry. This mechanism could potentially be exploited to achieve a therapeutic effect in other HIV-seropositive individuals.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740989      PMCID: PMC4442529          DOI: 10.1128/JVI.00118-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Spectrofluorimetric analysis of CCR5-delta 32 allele using real-time polymerase chain reaction: prevalence in southern Spanish HIV(+) patients and noninfected population.

Authors:  A Ruiz; J L Royo; A Rubio; S Borrego; M Leal; B Sánchez; A Nuñez-Roldán; G Antiñolo
Journal:  AIDS Res Hum Retroviruses       Date:  2001-01-20       Impact factor: 2.205

2.  Gene copy number regulates the production of the human chemokine CCL3-L1.

Authors:  Jane R Townson; Lisa F Barcellos; Robert J B Nibbs
Journal:  Eur J Immunol       Date:  2002-10       Impact factor: 5.532

3.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

Review 4.  Macrophage inflammatory protein-1.

Authors:  Patricia Menten; Anja Wuyts; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2002-12       Impact factor: 7.638

5.  Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

Authors:  B Julg; F Pereyra; M J Buzón; A Piechocka-Trocha; M J Clark; B M Baker; J Lian; T Miura; J Martinez-Picado; M M Addo; B D Walker
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

6.  The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.

Authors:  S Aquaro; P Menten; S Struyf; P Proost; J Van Damme; E De Clercq; D Schols
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes.

Authors:  A Muñoz; A J Kirby; Y D He; J B Margolick; B R Visscher; C R Rinaldo; R A Kaslow; J P Phair
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-15

8.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

9.  The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels.

Authors:  H W Sheppard; W Lang; M S Ascher; E Vittinghoff; W Winkelstein
Journal:  AIDS       Date:  1993-09       Impact factor: 4.177

Review 10.  Human gene copy number variation and infectious disease.

Authors:  Edward J Hollox; Boon-Peng Hoh
Journal:  Hum Genet       Date:  2014-06-05       Impact factor: 4.132

View more
  19 in total

Review 1.  HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.

Authors:  Jonathan Herskovitz; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-23       Impact factor: 4.147

2.  Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel.

Authors:  Y K Kiros; H Elinav; A Gebreyesus; H Gebremeskel; J Azar; D Chemtob; H Abreha; D Elbirt; E Shahar; M Chowers; D Turner; Z Grossman; A Haile; R E Sutton; S L Maayan; D Wolday
Journal:  HIV Med       Date:  2018-10-14       Impact factor: 3.180

Review 3.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

4.  Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts.

Authors:  Anju Bansal; Sarah Sterrett; Nathan Erdmann; Andrew O Westfall; Jodie Dionne-Odom; Edgar T Overton; Paul A Goepfert
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

5.  Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression.

Authors:  Evan S Jacobs; Sheila M Keating; Mohamed Abdel-Mohsen; Stuart L Gibb; John W Heitman; Heather C Inglis; Jeffrey N Martin; Jinbing Zhang; Zhanna Kaidarova; Xutao Deng; Shiquan Wu; Kathryn Anastos; Howard Crystal; Maria C Villacres; Mary Young; Ruth M Greenblatt; Alan L Landay; Stephen J Gange; Steven G Deeks; Elizabeth T Golub; Satish K Pillai; Philip J Norris
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

6.  Immune development in HIV-exposed uninfected children born to HIV-infected women.

Authors:  Maristela Miyamoto; Aída F T B Gouvêa; Erika Ono; Regina Célia M Succi; Savita Pahwa; Maria Isabel de Moraes-Pinto
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-06-01       Impact factor: 1.846

Review 7.  Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.

Authors:  Elena Gonzalo-Gil; Uchenna Ikediobi; Richard E Sutton
Journal:  Yale J Biol Med       Date:  2017-06-23

8.  Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

Authors:  Marcus Buggert; Son Nguyen; Laura M McLane; Maria Steblyanko; Nadia Anikeeva; Dominic Paquin-Proulx; Perla M Del Rio Estrada; Yuria Ablanedo-Terrazas; Kajsa Noyan; Morgan A Reuter; Korey Demers; Johan K Sandberg; Michael A Eller; Hendrik Streeck; Marianne Jansson; Piotr Nowak; Anders Sönnerborg; David H Canaday; Ali Naji; E John Wherry; Merlin L Robb; Steven G Deeks; Gustavo Reyes-Teran; Yuri Sykulev; Annika C Karlsson; Michael R Betts
Journal:  PLoS Pathog       Date:  2018-04-13       Impact factor: 6.823

9.  Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda.

Authors:  Alex Kayongo; Elena Gonzalo-Gil; Emrah Gümüşgöz; Anxious J Niwaha; Fred Semitala; Robert Kalyesubula; Bernard S Bagaya; Moses L Joloba; Richard E Sutton
Journal:  J Acquir Immune Defic Syndr       Date:  2018-11-01       Impact factor: 3.731

Review 10.  Evolution and Diversity of Immune Responses during Acute HIV Infection.

Authors:  Samuel W Kazer; Bruce D Walker; Alex K Shalek
Journal:  Immunity       Date:  2020-11-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.